Health experts have called for more research into the effectiveness of the new drug psoriasis medications, after finding some patients are experiencing more severe side effects than expected.
In a letter to the U.S. Food and Drug Administration, the American Academy of Allergy, Asthma and Immunology (AAASI) called for a review of how the drugs are used in the United States, saying a recent report by the US Department of Health and Human Services (HHS) showed that more than 3,000 people had been diagnosed with psorosis, which is caused by an infection with the bacteria psoriaspora.
In the letter, the group also asked for a study on the impact of the drugs on other chronic conditions such as diabetes and asthma.
In recent months, the FDA has approved three drugs for the treatment of psorasia, all from the drug company Merck, which also makes the psorabies.
They are the drug Rituxan, an oral version of the drug metronidazole, and psilocybin, an alternative drug used for treating depression and anxiety.
The FDA has given its final approval for two drugs to treat psoriosis, and is expected to finalize its approval for a third, called Lomustein, in the next few weeks.
But some critics have expressed concern that the drugs, which are approved for treating other conditions, may not be effective in psorasis.
Some patients have also reported that their symptoms worsened after using psorites medications, and have suggested that it could be a result of the medications not being able to kill the bacteria that causes psoria.
But the FDA said that, although the new drugs are approved to treat other chronic diseases, they do not prevent psorases infections, and patients should continue to use the drugs for other conditions.
The group called for the FDA to look at how to improve psoraxis drugs.
It also said the FDA should include an overview of psoriatic symptoms and the potential side effects of the medicines, including pain and dizziness.
“In the next several months, we expect to see a lot of information that will help us better understand what’s happening with these drugs and what their effectiveness is,” said Dr. John R. Reif, director of the university-based psoriatry clinic at the University of Minnesota.
“That’s why I would like the FDA, for example, to look more closely at the safety data.
We need that information to make sure it’s safe and effective.”
In recent weeks, some patients have been using the new medications for longer periods of time, sometimes up to three weeks, said Dr, Karen L. Davis, the president of the American Psoriasis Foundation, which advocates for psoricide treatments.
Davis said she believes psorids are getting more severe because of the use of the antibiotics, but that the drug companies should have more information about how their drugs work, which she said would help prevent side effects.
“We need to know more about what’s going on with the drugs.
We don’t know enough about what we’re using, we don’t have enough information about the side effects,” Davis said.”
It’s an issue that is getting worse.
It’s an important one, and we need to understand what is going on,” she added.
The new drug approved by the FDA is Ritixan, which was approved in February to treat patients with psoriasis.
Its approval came after a six-month clinical trial of more than 1,000 patients, which showed that the new treatment was effective in reducing psoritis symptoms in about half the patients.
The study found that patients who received the drug were less likely to have other infections and more likely to report having fewer side effects, such as fatigue, bloating and headaches.
In March, Merck also announced it was developing a psorid drug that would be used to treat the condition, and the company has scheduled a launch for October in a clinical trial in the U, US.
The company also said it was expanding a study into the safety of the psoralis drug Rifampin, which has been used in patients with chronic psoratic arthritis for the past decade.
The drug is expected not to be approved for use in the US until 2020, but the company said the approval was contingent on the FDA finding that it is safe and has no side effects in people over age 65.
A Merck spokesperson declined to comment on whether the company planned to launch a drug for psoralitis in the near future.
The agency approved two more drugs for treating psoritic infections earlier this month, and another drug is scheduled for approval in 2018.